DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
暂无分享,去创建一个
B. Le Goff | D. Heymann | K. Mori | F. Redini | S. Battaglia | B. L. Goff | C. Charrier | Kanji Mori
[1] C. Jacobs,et al. Oscillatory fluid flow-induced shear stress decreases osteoclastogenesis through RANKL and OPG signaling. , 2006, Bone.
[2] S. M. Sims,et al. Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.
[3] E. Schwarz,et al. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone , 2005, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[4] M. Malaise,et al. Interleukin-6: An osteotropic factor influencing bone formation? , 2005, Bone.
[5] N. Nonomura,et al. Prostate cancer mediates osteoclastogenesis through two different pathways. , 2005, Cancer letters.
[6] 井上 均. Prostate cancer mediates osteoclastogenesis through two different pathways , 2005 .
[7] R. Vessella,et al. Osteoprotegerin in prostate cancer bone metastasis. , 2005, Cancer research.
[8] S. Théoleyre,et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.
[9] C. Colombeix,et al. Downregulation of Osteoblast Markers and Induction of the Glial Fibrillary Acidic Protein by Oncostatin M in Osteosarcoma Cells Require PKCδ and STAT3 , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[10] M. Padrines,et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. , 2004, Biochimica et biophysica acta.
[11] J. Chirgwin,et al. Tumor-bone cellular interactions in skeletal metastases. , 2004, Journal of musculoskeletal & neuronal interactions.
[12] Kwan Tat Steeve,et al. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004 .
[13] W. Dougall,et al. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. , 2003, Cancer research.
[14] J. Chirgwin,et al. Transforming growth factor-beta in osteolytic breast cancer bone metastases. , 2003, Clinical orthopaedics and related research.
[15] Hong-Hee Kim,et al. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. , 2003, Biochemical and biophysical research communications.
[16] T. Guise. The vicious cycle of bone metastases. , 2002, Journal of musculoskeletal & neuronal interactions.
[17] G. Mundy. Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.
[18] F. Hamdy,et al. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. , 2002, Cancer research.
[19] G. Risbridger,et al. An in vivo model of prostate carcinoma growth and invasion in bone , 2002, Cell and Tissue Research.
[20] P. Kostenuik,et al. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] L. Hofbauer,et al. Receptor activator of nuclear factor‐κB ligand and osteoprotegerin , 2001 .
[22] A. Mizokami,et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. , 2001, The Journal of clinical investigation.
[23] R. Vessella,et al. Osteoprotegerin and rank ligand expression in prostate cancer. , 2001, Urology.
[24] E. Keller,et al. Interleukin-6 and prostate cancer progression. , 2001, Cytokine & growth factor reviews.
[25] R. Rizzoli,et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer , 2000, British Journal of Cancer.
[26] D. Lacey,et al. The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts , 1999, The Journal of cell biology.
[27] S. Morony,et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[28] J. Simons,et al. Characterization of the role of IL‐6 in the progression of prostate cancer , 1999, The Prostate.
[29] S. Morony,et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.
[30] H. Yasuda,et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.
[31] B. Bonavida,et al. Dexamethasone enhances expression of membrane and soluble interleukin-6 receptors by prostate carcinoma cell lines. , 1998, Anticancer Research.
[32] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[33] N. Clarke,et al. Morphometric evidence for bone resorption and replacement in prostate cancer. , 1991, British journal of urology.
[34] M. Hansen,et al. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. , 1989, Journal of immunological methods.
[35] S Paget,et al. THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .
[36] D. Heymann,et al. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. , 2006, International journal of oncology.
[37] M. Hansen,et al. Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] S. Kwan Tat,et al. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004, Cytokine & growth factor reviews.
[39] R. Kitazawa,et al. Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. , 2003, The Journal of biological chemistry.
[40] J. Chirgwin,et al. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. , 2000, Critical reviews in eukaryotic gene expression.
[41] Taylor Murray,et al. Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.
[42] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[43] J. Bingham. Letter: Lower oesophageal sphincter. , 1974, Lancet.